A multicenter retrospective study analyzed the clinical data of 171 EGFR mutant NSCLC patients on treatment with PD-1/PD-L1 ICI alone or in combination with CTLA4 inhibitor (53). This evidence concerns the gene CD274 and non-small cell lung carcinoma.